ADVFN Logo ADVFN

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P 500
5,671.28
-1.71%
US Tech 100
19,173.20
-2.53%
Dow Jones
42,481.04
-0.75%
Brent Oil
69.68
-0.06%
Bitcoin
79,926.52
-0.85%
Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. AN2 Therapeutics Inc (ANTX) Quote

AN2 Therapeutics Inc

AN2 Therapeutics Inc (ANTX)

NASDAQ
1.32
0.01
( 0.76% )
Updated: 10:06:43
Delayed by 15 minutes
Advanced chart

Empower your portfolio: Real-time discussions and actionable trading ideas.

Premium

Key stats and details

Current Price
1.32
Bid
1.30
Ask
1.32
Volume
11,083
1.30 Day's Range 1.32
0.87 52 Week Range 3.88
Market Cap
39.44M
Previous Close
1.31
Open
1.30
Last Trade
2
@
1.3199
Last Trade Time
10:08:02
Financial Volume
$ 14,507
VWAP
1.309
Average Volume (3m)
151,631
Shares Outstanding
29,878,890
Dividend Yield
-
PE Ratio
-0.60
Earnings Per Share (EPS)
-2.17
Revenue
-
Net Profit
-64.73M

About AN2 Therapeutics Inc

AN2 Therapeutics Inc is a clinical-stage biopharmaceutical company developing treatments for rare, chronic, and serious infectious diseases with high unmet needs. The initial product candidate is epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial, or NT... AN2 Therapeutics Inc is a clinical-stage biopharmaceutical company developing treatments for rare, chronic, and serious infectious diseases with high unmet needs. The initial product candidate is epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial, or NTM, lung disease. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
www.an2therapeutics.com
Headquarters
Dover, Delaware, USA
Founded
-
AN2 Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker ANTX. The last closing price for AN2 Therapeutics was $1.31. Over the last year, AN2 Therapeutics shares have traded in a share price range of $ 0.87 to $ 3.88.

AN2 Therapeutics currently has 29,878,890 shares outstanding. The market capitalization of AN2 Therapeutics is $39.14 million. AN2 Therapeutics has a price to earnings ratio (PE ratio) of -0.60.

Ask ADVFN Intelligence (AI)

ANTX Latest News

More News

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
February 28 2025
ANTX (0.76%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
February 28 2025
ANTX (0.76%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
February 28 2025
ANTX (0.76%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
February 28 2025
ANTX (0.76%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
January 07 2025
ANTX (0.76%)
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.1815.78947368421.141.351.092071601.19072255CS
40.2321.10091743121.091.351.04991810501.14104525CS
12-0.0983-6.930832687021.41831.451.04991516311.22831277CS
260.27526.31578947371.0451.6750.9753253131.21127953CS
52-1.59-54.63917525772.913.880.873770811.53381223CS
156-15.53-92.166172106816.8523.580.871919914.37002703CS
260-15.53-92.166172106816.8523.580.871919914.37002703CS

ANTX - Frequently Asked Questions (FAQ)

What is the current AN2 Therapeutics share price?
The current share price of AN2 Therapeutics is $ 1.32
How many AN2 Therapeutics shares are in issue?
AN2 Therapeutics has 29,878,890 shares in issue
What is the market cap of AN2 Therapeutics?
The market capitalisation of AN2 Therapeutics is USD 39.14M
What is the 1 year trading range for AN2 Therapeutics share price?
AN2 Therapeutics has traded in the range of $ 0.87 to $ 3.88 during the past year
What is the PE ratio of AN2 Therapeutics?
The price to earnings ratio of AN2 Therapeutics is -0.6
What is the reporting currency for AN2 Therapeutics?
AN2 Therapeutics reports financial results in USD
What is the latest annual profit for AN2 Therapeutics?
The latest annual profit of AN2 Therapeutics is USD -64.73M
What is the registered address of AN2 Therapeutics?
The registered address for AN2 Therapeutics is 850 NEW BURTON ROAD, SUITE 201, KENT, DOVER, DELAWARE, 19904
What is the AN2 Therapeutics website address?
The website address for AN2 Therapeutics is www.an2therapeutics.com
Which industry sector does AN2 Therapeutics operate in?
AN2 Therapeutics operates in the PHARMACEUTICAL PREPARATIONS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
CAPSCapstone Holding Corp
$ 3.60
(1,340.00%)
37.46k
RDFNRedfin Corporation
$ 10.28
(76.63%)
40.98M
STSSSharps Technology Inc
$ 0.4979
(67.81%)
152.47M
CKPTCheckpoint Therapeutics Inc
$ 4.06
(64.37%)
25.25M
MLYSMineralys Therapeutics Inc
$ 15.6399
(48.67%)
5.44M
SXTCChina SXT Pharmaceuticals Inc
$ 3.02
(-29.98%)
55.04k
MNDRMobile health Network Solutions
$ 2.11
(-26.76%)
156.88k
ABLVAble View Global Inc
$ 1.32
(-24.14%)
433.68k
MSTXTidal Trust II Defiance Daily Target 2x Long MSTR ETF
$ 21.7794
(-24.02%)
4.93M
ALBTAvalon GloboCare Corporation
$ 5.59
(-22.68%)
87k
STSSSharps Technology Inc
$ 0.4979
(67.81%)
152.2M
ICONIcon Energy Corporation
$ 0.1516
(-10.19%)
77.5M
SPRCSciSparc Ltd
$ 0.4145
(29.69%)
72.62M
TSLLDirexion Daily TSLA Bull 2X Trust ETF
$ 8.895
(-16.56%)
52.65M
BTOGBit Origin Ltd
$ 0.5158
(-16.81%)
46.99M

ANTX Financials

Financials

ANTX Discussion

View Posts
glenn1919 glenn1919 3 months ago
ANTX.....................https://stockcharts.com/h-sc/ui?s=ANTX&p=W&b=5&g=0&id=p86431144783
๐Ÿ‘๏ธ0
glenn1919 glenn1919 3 months ago
ANTX........................https://stockcharts.com/h-sc/ui?s=ANTX&p=W&b=5&g=0&id=p86431144783
๐Ÿ‘๏ธ0
TrendTrade2016 TrendTrade2016 3 months ago
ANTX NEXT WEEK WATCH
๐Ÿ‘๏ธ0
stocksrising stocksrising 4 months ago
Open market purchase always welcomed :)..even if tiny ๐Ÿ˜œ

Common Stock-CEO
11/18/2024
50,000
A
$0.9994
1,065,76
๐Ÿ‘๏ธ0
TrendTrade2016 TrendTrade2016 4 months ago
ANTX MINI BIO BEAST
๐Ÿ‘๏ธ 1
stocksrising stocksrising 4 months ago
I havenโ€™t done much DD on this bio, but it seems they have several readouts within 6-12mos. that could propel stock higher (especially with the $$$ runway position)โ€ฆ as you know, any biotech is risky but I like the odds on this one and starter position is small for nowโ€ฆI did copy this from release that I found appealing:

Boron Chemistry Pipeline

Additional development programs are underway and focused on targets in infectious diseases and oncology with high unmet needs. The Company anticipates delivering up to three development compounds in 2025.

Global Health

In October, the Company announced that it received a second-year continuation of a research grant from the Bill & Melinda Gates Foundation to discover novel boron containing small molecules for the treatment of tuberculosis and malaria. The Company will continue its efforts to tackle global health disease through non-dilutive funding.
๐Ÿ‘๏ธ0
eyeownu eyeownu 4 months ago
NOPE. took my looses moved them over to $EBS and made it all back. do you notice anything promising that warrants investing in this company besides the cash on hand?
๐Ÿ‘๏ธ0
stocksrising stocksrising 4 months ago
Picked up a bit more down here at $1ish, you still in??
๐Ÿ‘๏ธ0
Monksdream Monksdream 7 months ago
ANTX new 52 week low
๐Ÿ‘๏ธ0
Monksdream Monksdream 8 months ago
ANTX under $3
๐Ÿ‘๏ธ0
eyeownu eyeownu 8 months ago
looking good
๐Ÿ‘๏ธ0
glenn1919 glenn1919 8 months ago
ANTX..............https://stockcharts.com/h-sc/ui?s=ANTX&p=W&b=5&g=0&id=p86431144783
๐Ÿ‘๏ธ0
GO4AWILDRIDE GO4AWILDRIDE 11 months ago
FROM 3/28 NEWS:

Cash, cash equivalents, and investments of $134.5 million at December 31, 2023

GO4AWILDRIDE
๐Ÿ‘๏ธ0
GO4AWILDRIDE GO4AWILDRIDE 11 months ago
THE FOLLOWING FROM THE 3/28 NEWS:

โ€œAN2โ€™s cash position remains strong as we advance our innovative boron-based pipeline. Following the recent meeting of the independent Data Safety Monitoring Board, we continue to believe in the potential of epetraborole to become an important component of the backbone therapy for NTM lung disease,โ€ said Eric Easom, Co-Founder, President and Chief Executive Officer. โ€œPatients enrolled in the epetraborole Phase 2/3 trial in treatment refractory lung disease caused by MAC continue to be dosed while new enrollment in the Phase 3 part of the trial remains paused. Patients in the Phase 2 trial have reached the six-month mark, and we plan to report topline results this summer. Analysis of the baseline patient demographics from the trial show a highly complex and refractory patient population, which we plan to discuss with the FDA in the coming months.โ€

GO4AWILDRIDE
๐Ÿ‘๏ธ0
GO4AWILDRIDE GO4AWILDRIDE 11 months ago
Monksdream

Did you read the 3/28 news from the compay?

Seems like the market is looking to chase the price up.

GLTU

GO4AWILDRIDE
๐Ÿ‘๏ธ0
GO4AWILDRIDE GO4AWILDRIDE 11 months ago
Monksdream

Seems like a nice rebound is starting to occur.

GLTU

GO4AWILDRIDE
๐Ÿ‘๏ธ0
Monksdream Monksdream 1 year ago
ANTX new 52 week low
๐Ÿ‘๏ธ0
Monksdream Monksdream 1 year ago
ANTX new 52 week low
๐Ÿ‘๏ธ0
Monksdream Monksdream 1 year ago
ANTX new 52 week low
๐Ÿ‘๏ธ0

Your Recent History

NASDAQ
ANTX
AN2 Therapeutics
BIT
P1IGA1
BNP Paribas Issuance
AMEX
MDEV
First Trust Indxx Medica...
AMEX
IWM
iShares Russell 2000
NASDAQ
NAMS
NewAmsterdam Pharma Comp...
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

United States
Company
Business
Popular
Get The App
App Store
Google Play

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

ยฉ 2025 ADVFN PLC - All Rights Reserved

Go Ad-Free

Subscribe to Ad free and enjoy an ad-free experience

No Ads

Try Now

Keep the Ads